Studies related to Cognitive Decline and Oxiracetam

Oxiracetam In The Treatment Of Multi-infarct Dementia

Effect Decrease
Trial Design Non-controlled trial
Trial Length 1-6 months
Number of Subjects 12
Sex Both Genders
Age Range 45-64, 65+
Notes for this study:
12 weeks supplementation of oxiracetam (400mg for 4 weeks, building up to 1,200mg for 4 weeks) was able to provide a modest improvement on clinical ratings of cognition by about 1 point (on a 5 point scale) and seemed to favor verbal improvements.

Full details on all 5 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.